Literature DB >> 3102090

High-dose ifosfamide alone and in combination for solid malignancies in childhood.

M Gasparini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3102090     DOI： 10.1007/bf00647442

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


× No keyword cloud information.
  5 in total

1.  Adolescents and Young Adults (AYAs) With Initially Localized and Metastatic Bone Sarcomas: A Retrospective Single Center Analysis of Side Effect Management.

Authors:  Christoph Minichsdorfer; Oskar Steinbrecher; Marita KÖlz; Maximilian Schmid; Markus Raderer; Thomas Brodowicz; Wolfgang Lamm
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

2.  Toxicity of high-dose ifosfamide in children.

Authors:  S M Davies; A D Pearson; A W Craft
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group.

Authors:  R Skinner; S J Cotterill; M C Stevens
Journal:  Br J Cancer       Date:  2000-05       Impact factor: 7.640

4.  Methotrexate, doxorubicin, and cisplatinum regimen is still the preferred option for osteosarcoma chemotherapy: A meta-analysis and clinical observation.

Authors:  Dapeng Yu; Shuisheng Zhang; Alei Feng; Deguo Xu; Qingshan Zhu; Yantao Mao; Yi Zhao; Yajuan Lv; Cuiping Han; Rujun Liu; Yuan Tian
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

5.  Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.

Authors:  Neyssa M Marina; Sigbjørn Smeland; Stefan S Bielack; Mark Bernstein; Gordana Jovic; Mark D Krailo; Jane M Hook; Carola Arndt; Henk van den Berg; Bernadette Brennan; Bénédicte Brichard; Ken L B Brown; Trude Butterfass-Bahloul; Gabriele Calaminus; Heike E Daldrup-Link; Mikael Eriksson; Mark C Gebhardt; Hans Gelderblom; Joachim Gerss; Robert Goldsby; Allen Goorin; Richard Gorlick; Holcombe E Grier; Juliet P Hale; Kirsten Sundby Hall; Jendrik Hardes; Douglas S Hawkins; Knut Helmke; Pancras C W Hogendoorn; Michael S Isakoff; Katherine A Janeway; Heribert Jürgens; Leo Kager; Thomas Kühne; Ching C Lau; Patrick J Leavey; Stephen L Lessnick; Leo Mascarenhas; Paul A Meyers; Hubert Mottl; Michaela Nathrath; Zsuzsanna Papai; R Lor Randall; Peter Reichardt; Marleen Renard; Akmal Ahmed Safwat; Cindy L Schwartz; Michael C G Stevens; Sandra J Strauss; Lisa Teot; Mathias Werner; Matthew R Sydes; Jeremy S Whelan
Journal:  Lancet Oncol       Date:  2016-08-25       Impact factor: 41.316
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.